Human Genome Sciences, Inc (HGSI)

[PETERDENIEL2003]

HEART DISEASE
In the area of heart disease, Cytori is sponsoring three European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction (heart attack) and chronic myocardial ischemia (a severe form of coronary artery disease).

Heart disease is the number one cause of death in the U.S., Europe, and the majority of other countries around the world. Advanced heart disease also accounts for many disabilities, lost productivity, and diminished lifestyle. Cytori performed pre-clinical (in the laboratory) studies that suggested a restoration of heart function following the application of adipose-derived stem and regenerative cells (ADRCs). Cytori is conducting two safety and feasibility trials, the APOLLO and PRECISE trials, in the areas of acute heart attack and chronic myocardial ischemia, respectively. Currently, Cytori is enrolling a pivotal European trial, ADVANCE, for acute myocardial infarction.

ADVANCE
Acute Myocardial Infarction (Europe)
>>Learn more on ClinicalTrials.gov

http://www.clinicaltrials.gov/ct2/show/NCT01216995?term=ADVANCE%20Cytori&rank=1